Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain  by Puig-Asensio, M. et al.
Epidemiology and predictive factors for early and late mortality in
Candida bloodstream infections: a population-based surveillance in Spain
M. Puig-Asensio1, B. Padilla2,3, J. Garnacho-Montero4, O. Zaragoza5, J. M. Aguado6, R. Zaragoza7, M. Montejo8, P. Mu~noz2,3,
I. Ruiz-Camps1, M. Cuenca-Estrella5 and B. Almirante1 on behalf of the CANDIPOP Project* and GEIH-GEMICOMED (SEIMC)
and REIPI
1) Infectious Diseases Department, Medicine Department, Hospital Universitari Vall d′Hebron, Universitat Autonoma de Barcelona, Barcelona, 2) Department of
Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Mara~non, Madrid, 3) Department of Medicine, Universidad Complutense
de Madrid, CIBER de Enfermedades Respiratorias (CIBER RES), CD06/06/0058, Palma de Mallorca, 4) Critical Care and Emergency Department, Hospital
Universitario Virgen del Rocıo, Seville, 5) Department of Mycology, Spanish National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain,
6) Infectious Diseases Unit, Medicine Department, University Hospital 12 de Octubre, Instituto de Investigacion I+12, Universidad Complutense de Madrid,
Madrid, 7) Intensive Care Medicine Department, Hospital Universitario Dr Peset, Valencia and 8) Infectious Diseases Unit, Hospital Universitario de Cruces,
Bilbao, Spain
Abstract
A prospective, multicentre, population-based surveillance programme for Candida bloodstream infections was implemented in ﬁve
metropolitan areas of Spain to determine its incidence and the prevalence of antifungal resistance, and to identify predictors of death.
Between May 2010 and April 2011, Candida isolates were centralized to a reference laboratory for species identiﬁcation by DNA sequencing
and for susceptibility testing by EUCAST reference procedure. Prognostic factors associated with early (0–7 days) and late (8–30 days)
death were analysed using logistic regression modelling. We detected 773 episodes: annual incidence of 8.1 cases/100 000 inhabitants, 0.89/
1000 admissions and 1.36/10 000 patient-days. Highest incidence was found in infants younger than 1 year (96.4/100 000 inhabitants).
Candida albicans was the predominant species (45.4%), followed by Candida parapsilosis (24.9%), Candida glabrata (13.4%) and Candida
tropicalis (7.7%). Overall, 79% of Candida isolates were susceptible to ﬂuconazole. Cumulative mortality at 7 and 30 days after the ﬁrst
episode of candidaemia was 12.8% and 30.6%, respectively. Multivariate analysis showed that therapeutic measures within the ﬁrst 48 h may
improve early mortality: antifungal treatment (OR 0.51, 95% CI 0.27–0.95) and central venous catheter removal (OR 0.43, 95% CI 0.21–
0.87). Predictors of late death included host factors (e.g. patients’ comorbid status and signs of organ dysfunction), primary source (OR 1.63,
95% CI 1.03–2.61), and severe sepsis or septic shock (OR 1.77, 95% CI 1.05–3.00). In Spain, the proportion of Candida isolates
non-susceptible to ﬂuconazole is higher than in previous reports. Early mortality may be improved with strict adherence to guidelines.
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Introduction
European surveillance studies show that the incidence of
Candida bloodstream infections (BSI) ranges from nearly 3 to
8.6 per 100 000 population per year [1–6].
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Despite the introduction of new antifungal agents, this
infection remains a severe disease associated with signiﬁcant
mortality [7]. Hence, changes in clinical practices have already
occurred, with prophylactic and empirical antifungal therapies
in high-risk patients. However, these strategies may be linked
to a shift towards non-albicans species and the emergence of
isolates with decreased ﬂuconazole susceptibility [8].
The epidemiology of candidaemia has been extensively
studied in the USA [9–12] and northern and central Europe. In
Spain, however, data are limited to surveys conducted in
speciﬁc areas [6,13] or tertiary centres [14]. Furthermore, we
are lacking information about the reasons for the poor current
outcome of candidaemia. Studies that have reported determi-
nants of mortality are based on retrospective data or have
focused on the impact of therapeutic measures from a
restricted viewpoint [15–20].
We conducted a population-based surveillance for Candida
BSI in Spain to determine its incidence and the distribution and
susceptibility pattern of Candida species, and to examine
prognostic risk factors for mortality.
Materials and Methods
Setting, patients and study design
The CANDIPOP study is a prospective, population-based
surveillance programme on Candida BSI, conducted from May
2010 to April 2011 in 29 hospitals located in ﬁve of the largest
municipal areas of Spain: Barcelona, Bilbao, Madrid, Seville and
Valencia (population 9 498 980, or 20% of the Spanish
population). Patients were identiﬁed by local laboratories
and reported to study coordinators, who collected data using
a standardized case report form. Demographic characteristics,
underlying conditions, predisposing risk factors within the
preceding month, and 30-day follow-up outcome were
recorded in a dedicated database created for the study. Given
the observational nature of this research, patients were
managed according to routine clinical care.
Audits were carried out to ensure that all cases were
reported. The study was approved by the local institutional
review boards, and written consent was obtained from
patients.
Deﬁnitions
Deﬁnitions have been described in a previous publication [6].
In brief, an incident case was the ﬁrst positive Candida spp.
blood culture. Candidaemias occurring >30 days after the
incident episode or isolation of a different Candida species
after the initial case were considered new episodes.
Outpatient-acquired caseswere candidaemias detected ≤2 days
after hospitalization. The Charlson index was used to represent
comorbidity in adults [21]. Sepsis, severe sepsis or septic shock
were recorded on the day of candidaemia [22]. Proven
catheter-related candidaemia has been described elsewhere
[23]. Timing to central venous catheter (CVC) removal and to
antifungal administration was the interval between incident
blood culture and implementation of these measures. Adequate
antifungal treatmentwas the use of the correct dose of antifungal
agent for a susceptible Candida isolate (see Supplementary
material, Table S1). Patients receiving >3 days of systemic
antifungal drug before the ﬁrst positive blood culture were
considered to have breakthrough candidaemias.
Incidence
Population and age-speciﬁc incidence rates were expressed as
number of cases per 100 000 population, using the 2011
Spanish national census data. Overall incidence of hospitals was
calculated using as denominators the summed number of
admissions and patient-days of each hospital during the study
period.
Microbiological studies
Candida isolates were forwarded to a reference laboratory, the
Spanish National Centre for Microbiology in Madrid, for
species conﬁrmation and antifungal susceptibility testing.
Species identiﬁcation was performed by sequencing the
internal transcribed spacer (ITS) regions from ribosomal
DNA. ITS1 and ITS2 regions were directly ampliﬁed by PCR
from yeast suspensions and sequenced using universal primers
[24,25]. Susceptibility to antifungal drugs and interpretation of
resistance rates were investigated according to the protocols
[26,27] and clinical breakpoints of the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) [http://
www.eucast.org/clinical_breakpoints/]. Of note, Candida glab-
rata and Candida guilliermondii are considered intermediate or
resistant to ﬂuconazole, as there is insufﬁcient evidence on
whether the wild-type population of these pathogens can be
considered ﬂuconazole-susceptible.
Data analysis
Quantitative variables are reported as median and interquar-
tile range (IQR) and qualitative variables as number (%).
Categorical data were analysed using the chi-squared or Fisher
exact test. Signiﬁcance was set at a p-value of <0.05.
Prognostic factors associated with early (0–7 days) and late
(8–30 days) death were assessed using logistic regression
analysis. To preserve the assumption of independence of
observations, only the ﬁrst episode of candidaemia recorded
for an individual patient was included in this analysis. Neonates
and infants younger than 1 year were excluded from the
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predictor analysis because epidemiology and risk factors for
candidaemia might differ from those described in adults and
older children. Episodes caused simultaneously by different
Candida species were also excluded. Variables with p <0.1 in
the univariate analysis and considered clinically relevant were
entered in a multivariate model. The best model was selected
according to Mallows′ Cp statistic. Model adequacy was assessed
by the Hosmer–Lemeshow goodness-of-ﬁt test and the area
under the receiver operating characteristic curve. For early
mortality, it was decided a priori that antifungal treatment and
CVC removal would remain in the ﬁnal multivariate analysis
given the belief that these factors might be associated with
outcome. Potential confounders of therapy were maintained in
the multivariate model. No interactions between variables were
found. Statistical analyses were performed with Microsoft
SPSS-PC+, version 15.0 (SPSS, Chicago, IL, USA).
Results
Incidence rates
We identiﬁed 773 episodes of Candida BSI, yielding an annual
incidence of 8.1 cases/100 000 inhabitants, 0.89/1000 admis-
sions and 1.36/10 000 patient-days. Differences in incidence
rates between geographical areas are shown in the Supple-
mentary material (Table S2). Highest age-speciﬁc incidence
was observed in infants younger than 1 year (96.4/100 000
inhabitants), and a later peak occurred in persons aged 71–
80 years (26.5/100 000 inhabitants) (Fig. 1).
Study population
Twenty-one patients declined to participate. Hence, this
report is based on 752 episodes of candidaemia detected in
729 patients. Baseline characteristics of the study population
are outlined in Table 1. Ninety (12%) cases were
outpatient-acquired, and the remaining occurred among hos-
pitalized patients, including 264 (35.1%) admitted to the
intensive care unit. Median length of hospitalization before
Candida BSI was 22 days (IQR 13–39), and 356 (47.3%) cases
had recent healthcare exposure (i.e hospitalization within the
previous 3 months).
Clinical data
Sepsis was the clinical presentation of candidaemia in 512
(68.1%) cases. Regarding haematogenous dissemination, ocular
candidiasis was reported in 20 cases (2.7%), endocarditis in 14
(1.9%), and metastatic renal infection in three (0.4%). Central
nervous system involvement occurred in seven cases (0.9%), all
but one in infants. Excluding the 45 patients who survived
≤48 h, follow-up blood samples were obtained in 477 (67.5%)
cases at a median of 3 days (IQR 4–8). Of these, 144 (30.1%)
cases had persistent candidaemia.
Species distribution and antifungal susceptibility testing
In 159 cases, incident blood culture was polymicrobial: a
bacterial strain was identiﬁed in 145 (19.3%) and two different
Candida species were simultaneously isolated in 14 (1.9%).
Hence, 766 Candida strains were obtained from 752 episodes.
Candida albicans was the predominant species (348, 45.4%),
followed by Candida parapsilosis (191, 24.9%), C. glabrata (103,
13.4%), Candida tropicalis (59, 7.7%), Candida krusei (15, 2%),
and other rarer species (50, 6.5%). Differences in distribution
of Candida spp. between metropolitan areas are outlined in the
Supplementary material (Figure S1).
Compared with other Candida species, C. parapsilosis was
more likely to occur in children younger than 1 year (18.9%
versus 9.9%, p 0.001) and in catheter-related candidaemia
(48.1% versus 29.3%, p <0.001). Candida glabrata cases were
more frequent in persons older than 65 years (62.9% versus
43.4%, p <0.001) and where there was an abdominal source of
infection (8.2% versus 2.7%, p 0.011). Candida albicans was
more often related to previous colonization by the same
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FIG. 1. Annual incidence of candidaemia
by age in Spain from 2010 to 2011.
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Candida spp. (46.7% versus 30.3, p <0.001), and C. tropicalis to
haematological malignancies (17.5% versus 6.3%, p 0.005).
Regarding the impact of antifungal exposure within the
previous month, C. parapsilosis was more frequent in cases
with previous use of echinocandins (12.4% versus 4%,
p <0.001) and C. krusei with previous azole exposure (50%
versus 15%, p 0.003).
Table 2 shows antifungal susceptibility results. For ﬂuconaz-
ole, 79% (604/766) of Candida isolates were susceptible. The
resistance rate of C. tropicalis was 22% (13/59). However,
ﬂuconazole non-susceptible isolates (MIC ≥4 mg/L) were
uncommon in both C. albicans and C. parapsilosis (1% and 5%,
respectively). A single case of Candida kefyr was resistant to
amphotericin B (0.1%). Rates of resistance to echinocandins
were 0.3% (1/348) forC. albicans, 1% (1/103)C. glabrata, 3.4% (2/
59) C. tropicalis, and no resistance was found among C. krusei.
Therapeutic measures
Of 749 cases in 726 patients with available data, 137 (18.3%)
were receiving antifungal drugs at blood culture collection; 101
of these episodes were considered breakthrough candidaemias
that occurred while receiving azoles (62, 61.4%), echinocandins
(26, 25.7%) or amphotericin B (13, 12.9%). Overall, 673
(89.5%) episodes received targeted antifungal therapy for
candidaemia. Excluding the 137 cases receiving antifungal drugs
at candidaemia onset, treatment was started at a median time
of 2 days (IQR 1–3) after the incident blood culture. A detailed
description of therapies is provided in the Supplementary
material (Table S3).
Outcome and predictors of mortality
Nine patients were lost to follow-up before day 30 (three
before day 7). Overall, cumulative mortality at 7 and 30 days
TABLE 1. Baseline characteristics of study population and clinical data of candidaemia episodes according to Candida species,
Spain (2010–2011)
Characteristic
All cases
(N = 752)
Candida speciesa
C. albicans
(n = 337)
C. parapsilosis
(n = 185)
C. glabrata
(n = 97)
C. tropicalis
(n = 57)
C. krusei
(n = 14)
Demographics
Median age, years 63 (43–75) 65 (45–75) 54 (6–69.5) 71 (56.5–78.5) 68 (54.5–78.5) 54.5 (47.5–66.8)
Age <1 year 92 (12.2) 43 (12.8) 35 (18.9) 1 (1) 4 (7) –
Male sex 442 (58.8) 185 (54.9) 122 (65.9) 57 (58.8) 30 (52.6) 10 (71.4)
Outpatient 90 (12) 31 (9.2) 24 (13) 21 (21.6) 4 (7.1) 1 (7.1)
Days in hospital until Candida BSIb 22 (13–39) 20 (12–34) 28 (17–55) 23 (12.3–36.8) 20 (11–36.5) 24 (13–42.5)
Comorbidities
Diabetes mellitus 161 (21.4) 76 (22.6) 29 (15.7) 29 (29.9) 16 (28.1) 2 (14.3)
Malignancy (≤1 year) 257/749 (34.3) 101/334 (33.2) 54 (29.2) 42 (43.3) 25 (43.9) 7 (50)
Previous renal failure 194 (25.8) 106 (31.5) 32 (17.3) 26 (26.8) 14 (24.6) 3 (21.4)
Transplant recipient 48 (6.4) 11 (3.3) 15 (8.1) 10 (10.3) 5 (8.8) 3 (21.4)
Liver cirrhosis 32 (4.3) 13 (3.9) 4 (2.2) 5 (5.2) 2 (3.5) 2 (14.3)
HIV infection 16 (2.1) 6 (1.8) 1 (0.5) 3 (3.1) 1 (1.8) –
Risk factors for candidaemia
Central venous catheter 581/750 (77.5) 258 (76.6) 156/183 (85.2) 66 (68) 38 (66.7) 13 (92.9)
Total parenteral nutrition 365 (48.5) 176 (52.2) 95 (51.4) 41 (42.3) 20 (35.1) 8 (57.1)
Immunosuppressive therapyc 168 (22.3) 68 (20.2) 40 (21.6) 18 (18.6) 14 (24.6) 6 (42.9)
Neutropenia (<500 cell/mm3) 35 (4.7) 10 (3) 6 (3.2) 3 (3.1) 5 (8.8) 2 (14.3)
Intubation 188/751 (25) 98/336 (29.1) 51 (27.6) 16 (16.5) 7 (12.3) 4 (28.6)
Prior surgery (3 months) 382 (50.8) 181 (53.7) 98 (53) 47 (48.5) 27 (47.4) 5 (35.7)
Abdominal surgery 211 (28.1) 95 (28.2) 54 (29.2) 34 (35.1) 15 (26.3) 4 (28.6)
Prior antibiotic therapyc 699/748 (93.5) 324/334 (97) 165/184 (89.7) 87 (89.7) 54 (94.7) 11 (78.6)
Prior fungal therapyc 160/751 (21.3) 46 (13.6) 57 (30.8) 23/96 (24) 12 (21.1) 8 (57.1)
Azole exposure 117/750 (15.6) 37 (11) 34 (18.4) 20/96 (20.8) 7/56 (12.5) 7 (50)
Echinocandin exposure 45/751 (6) 9 (2.7) 23 (12.4) 5/96 (5.2) 4 (7) 2 (14.3)
Prior Candida colonization 284/750 (37.9) 157/336 (46.7) 50 (27) 42 (43.3) 18 (31.6) 4/13 (30.8)
Source of infection
Primary 423 (56.3) 202 (59.9) 89 (48.1) 54 (55.7) 33 (57.9) 8 (57.1)
Catheter-related 258 (34.3) 101 (30) 89 (48.1) 24 (24.7) 16 (28.1) 5 (35.7)
Urological 40 (5.3) 22 (6.5) 2 (1.1) 9 (9.3) 5 (8.8) –
Abdominal 25 (3.3) 9 (2.7) 5 (2.7) 8 (8.2) 3 (5.3) –
Others 6 (0.8) 3 (0.9) – 2 (2.1) – 1 (7.1)
Severity of infection
Bacteria in incident culture 145 (19.3) 63 (18.7) 38 (20.5) 20 (20.6) 10 (17.5) 5 (35.7)
Septic shock or severe sepsis 240 (31.9) 120 (35.6) 46 (24.9) 30 (30.9) 21 (36.8) 7 (50.7)
Therapeutic measures (≤48 h)
Adequate antifungal therapyd 428/749 (57.1) 203/337 (60.2) 121/184 (65.8) 23/96 (24)e 36/56 (64.3) 8/14 (57.1)
CVC removalf 275/575 (47.8) 127/253 (50.2) 70/156 (44.9) 38/66 (57.6) 15/38 (39.5) 7/13 (53.8)
Values are reported as no./total no (%) or median (interquartile range) unless otherwise indicated.
BSI, bloodstream infection; CVC, central venous catheter; HIV, human immunodeﬁciency virus.
aCases in which two Candida species were isolated on incident blood culture are not included.
bOnly includes nosocomial candidaemias, cases with positive blood culture after 2 days of hospitalization.
cWithin the preceding month. Immunosuppressive therapy includes corticoids, chemotherapy and other immunosuppressive drugs.
dAppropriateness of antifungal treatment in the ﬁrst 48 h was not available for three cases.
eWe considered that azole use in the ﬁrst 48 h was unsuitable for treating C. glabrata infections in 21 episodes. Among them, one patient died within 7 days.
fData regarding CVC removal in the ﬁrst 48 h were missing in six of 581 cases.
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after the ﬁrst episode of candidaemia was 12.8% (93/726) and
30.6% (220/720), respectively.
On univariate analysis, numerous factors were associated
with early mortality in patients older than 1 year (Table 3).
When adjusted by primary source of candidaemia and severity
of infection (severe sepsis or septic shock) in the multivariate
regression analysis, appropriate antifungal treatment within the
ﬁrst 48 h was the only factor independently associated with
lower mortality. To explore whether antifungal therapy was
affected by CVC removal, a secondary analysis was performed
in patients with CVCs. On multivariate analysis, adequate
antifungal treatment (OR 0.51, 95% CI 0.27–0.95) and having
the CVC removed (OR 0.43, 95% CI 0.21–0.87) within the ﬁrst
48 h remained associated with decreased early mortality.
Independent risk factors for late mortality were related to
host characteristics (age, immunosuppression), clinical presen-
tation of candidaemia (septic shock or severe sepsis and
primary infection), and signs of organ dysfunction (intubation
and previous renal replacement therapy) (Table 4). To further
assess the inﬂuence of CVC removal on late mortality,
separate logistic regression analyses were performed. The
possible beneﬁt of CVC removal on univariate analysis
disappeared after including host factors and clinical data in
the multivariate analysis (OR 0.72, 95% CI 0.43–1.22). Similar
results were obtained in patients with catheter-related candi-
daemia: none of the treatment-related factors were signiﬁ-
cantly associated with late mortality.
Because no paediatric severity of illness score was mea-
sured during the study and comorbidities may have an effect
on outcome, similar multivariate models for early and late
mortality were explored in the subgroup of adults (≥18 years).
After entering the Charlson index as an independent variable,
the beneﬁt of therapeutic measures on early mortality
remained stable. Conversely, the Charlson index was added
as a prognostic factor for late mortality (OR 1.13, 95% CI
1.00–1.28) (data not shown).
Discussion
Candidaemia remains a life-threatening infection, especially in
patients with severe underlying conditions. As our results
show, overall incidence of Candida BSI in Spain is 8.1/100 000
population. Although we lack comparative studies, our
incidence rate is similar to those of most population-based
studies conducted in the USA between 1992 and 2001 [9–12]
(6–8/100 000 population/year) and is comparable to a recent
national surveillance performed in Denmark [4] (8.6/100 000
population). However, it differs from most northern and
central European countries [2,3,5], which have described a
much lower disease burden (nearly 3–5.7/100 000 population)
and contrasts with the high rates in a contemporary US survey
conducted in Atlanta and Baltimore (13.3 and 26.2 cases/
100 000 population, respectively) [12]. In general, these
geographic variations probably reﬂect demographic differences
or variations in patient management.
In accordance with previous surveillance reports, the
highest incidence rates are at the extremes of age. Of note,
however, we found an unexpectedly high peak in children
younger than 1 year (96.4 cases/100 000 population) in
comparison with other European surveys [2–5] (range, 9.4–
20.7/100 000 population).This result diverges from the
TABLE 2. In vitro susceptibilities of Candida bloodstream isolates to different antifungalsa
Species
MIC (mg/L)
Value
Amphotericin
B Flucytosine Fluconazole Itraconazole Voriconazole Posaconazole Caspofungin Micafungin Anidulafungin
C.
albicans
GM 0.051 0.16 0.21 0.016 0.016 0.015 0.31 0.03 0.03
MIC90 0.12 0.5 0.25 0.015 0.015 0.015 0.5 0.03 0.03
Range 0.03–0.25 0.12–32 0.12–>64 0.015–>8 0.015–>8 0.015–8 0.12–2 0.03–1 0.03–0.25
C.
parapsilosis
GM 0.14 0.49 0.48 0.018 0.017 0.016 1.36 0.84 0.93
MIC90 0.25 0.25 1 0.03 0.03 0.015 2 2 2
Range 0.03–1 0.12–0.5 0.12–64 0.015–0.25 0.015–0.5 0.015–0.12 0.5–4 0.25–4 0.12–4
C.
glabrata
GM 0.106 0.133 3.074 0.127 0.12 0.124 0.44 0.031 0.031
MIC90 0.25 0.12 16 1 0.5 0.5 1 0.03 0.03
Range 0.03–0.5 0.12–>64 0.5–>64 0.015–>8 0.015–8 0.015–8 0.25–1 0.03–1 0.03–0.5
C.
tropicalis
GM 0.079 0.154 1.83 0.057 0.13 0.047 0.41 0.034 0.034
MIC90 0.12 0.12 >64 8 >8 8 0.5 0.03 0.03
Range 0.03–0.5 0.12–32 0.12–>64 0.015–>8 0.015–>8 0.015–>8 0.12–2 0.03–2 0.03–1
C.
krusei
GM 0.236 3.48 33.5 0.066 0.3 0.048 0.87 0.08 0.034
MIC90 0.5 4 64 0.25 0.5 0.12 1 0.12 0.03
Range 0.12–0.5 2–4 16–64 0.015–0.25 0.015–1 0.015–0.12 0.5–2 0.06–0.12 0.03–0.06
C.
guilliermondii
GM 0.067 0.127 3.22 0.22 0.12 0.075 0.9 033 0.5
MIC90 0.12 0.25 16 1 0.25 0.25 2 05 1
Range 0.03–0.12 0.12–0.25 0.12–32 0.06–2 0.06–0.25 0.015–0.25 0.5–2 0.25–0.5 0.25–1
C.
lusitaniae
GM 0.06 0.287 0.45 0.02 0.023 0.018 0.92 0.05 0.036
MIC90 0.25 >64 32 0.12 0.5 0.06 1 0.06 0.12
Range 0.03–0.25 0.12–>64 0.12–64 0.015–0.25 0.015–0.5 0.015––0.06 0.5–1 0.03–0.06 0.03–0.12
GM, geometric mean; MIC, minimum inhibitory concentration.
aThe table describes susceptibility of species with higher prevalence (n ≥10) in the CANDIPOP study.
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epidemiological trend towards the increasing relevance of the
elderly population as the most important age-speciﬁc group
affected by candidaemia [2,4,12]. We believe the high incidence
rate in our infants is inﬂuenced by at least two factors. First, all
the study regions included referral paediatric and neonatal
units for community hospitals from other areas, which could
have contributed to an overestimate of the incidence rates.
Second, there was a high percentage of C. parapsilosis in
children younger than 1 year in comparison with adults.
Although the relevance of C. parapsilosis in neonatal candida-
emia is well-recognized [28,29] and an endemic situation
cannot be ruled out [30] these results may reﬂect the
presence of nosocomial outbreaks and the need to improve
infection control practices. Therefore, further molecular
studies of C. parapsilosis strains are required, and particular
consideration should be given to ﬂuconazole prophylactic
therapy in low-birthweight neonates, according to guidelines
[31,32].
Over the last decade, there have been no substantial changes
in Candida species distribution in Spain. The only exception is a
possible increase in the percentage of C. glabrata, particularly in
the elderly. In the present study, C. glabrata was the third most
common species (13.4%), whereas in reports from the early
2000s its proportion was <9% [6,33]. Although these studies
involved different surveillance regions and are not entirely
comparable, the same trends have been reported in the USA
[10,11], Denmark and Finland [2,4]. It is suggested that the rise in
C. glabrata may be due to widespread azole use. However, this
association remains unclear, and other host factors and medical
practices may have contributed [34,35].
Our ﬁndings conﬁrm that ﬂuconazole susceptibility has
decreased in Spain. Earlier studies in Barcelona [6,36] showed
that >90% of Candida isolates were ﬂuconazole-susceptible,
whereas the present report documents ﬂuconazole suscepti-
bility at <80%. Although this decrease is mainly due to rises in
C. glabrata infection, we also found signiﬁcant ﬂuconazole
resistance in C. tropicalis strains (22%), never before reported
in Spain. Resistance to echinocandins was very low, except for
C. parapsilosis, which exhibited higher MICs than those of other
Candida species. The clinical relevance of these ﬁndings warrants
analysis in further studies because the correlation between MIC
and clinical response to echinocandins remains uncertain.
TABLE 3. Univariate and multivariate logistic regression analyses of prognostic factors for early mortality (0–7 days) in 629a
patients
Variable Alive (n = 547) Died (n = 82)
Univariate analysis Multivariate analysisb
OR (95% CI) p value OR (95% CI) p value
Host factors
Age, years 65.6 (51.3–76.0) 72.2 (55.4–80.2) 1.02 (1.01–1.04) 0.001 1.02 (1.01–1.04) 0.011
Male sex 317 (58) 57 (69.5) 1.65 (1.00–2.73) 0.048
Charlson indexc 2 (1–3) 3 (2–5) 1.23 (1.10–1.37) <0.001
Malignancy (≤1 year) 214/546 (39.2) 28/80 (35) 0.84 (0.52–1.36) 0.472
Transplant recipient 42 (7.7) 3 (3.7) 0.46 (0.14–1.51) 0.199
HIV infection 13 (2.4) 1 (1.2) 0.51 (0.07–3.93) 0.516
Immunosuppressive therapy 137 (25) 16 (19.5) 0.73 (0.41–1.30) 0.278
Neutropenia (<500 cell/mm3) 29 (5.3) 5 (6.1) 1.16 (0.44–3.01) 0.766
Abdominal surgery 166 (30.3) 20 (24.4) 0.74 (0.43–1.27) 0.272
Previous RRT 40 (7.3) 5 (6.1) 0.82 (0.32–2.15) 0.691
Intubation 111 (20.3) 21 (25.6) 1.35 (0.79–2.32) 0.272
Clinical data
Primary source 278 (50.8) 64 (78) 3.44 (1.99–5.96) <0.001 3.43 (1.90–6.19) <0.001
Catheter-related 208 (38) 11 (13.4) 0.25 (0.13–0.49) <0.001
Antifungal agent at time of blood
culture collection
91/545 (16.7) 16 (19.5) 1.21 (0.67–2.18) 0.528
Severe sepsis or septic shock 143 (26.1) 53 (64.6) 5.16(3.16–8.44) <0.001 6.56 (3.85–11.17) <0.001
Bacteria in incident culture 101 (18.5) 15 (18.3) 0.99 (0.54–1.80) 0.970
Candida species
C. albicans 249 (45.5) 38 (46.3) 1.03 (0.65–1.65) 0.889
C. parapsilosis 132 (24.1) 12 (14.6) 0.54 (0.28–1.03) 0.060
C. glabrata 77 (14.1) 15 (18.3) 1.37 (0.74–2.51) 0.315
C. tropicalis 43 (7.9) 8 (9.8) 1.27 (0.57–2.80) 0.559
C. krusei 10 (1.8) 4 (4.9) 2.75 (0.84–8.99) 0.093 3.10 (0.83–11.60) 0.092
Therapeutic measures (≤48 h)
Adequate antifungal treatment 306/544 (56.3) 25 (30.5) 0.34 (0.21–0.56) <0.001 0.35 (0.20–0.61) <0.001
CVC removald 206/416 (49.5) 13/55 (23.6) 0.32 (0.17–0.61) 0.001
Values are reported as no./total no (%) or median (interquartile range).
CI, conﬁdence interval; CVC, central venous catheter; HIV, human immunodeﬁciency virus; OR, odds ratio; RRT, renal replacement therapy.
aOnly the ﬁrst episode of candidaemia was included for patients with multiple episodes. Neonates and infants younger than 1 year, cases of candidaemia caused simultaneously by
different species of Candida, and two adult patients who were lost to follow up in this period were excluded from the analysis.
bThe best multivariate analysis model according to Mallows′ Cp statistic included the following variables: age, primary source, severe sepsis or septic shock, Candida krusei and
adequate antifungal treatment (Hosmer–Lemeshow p 0.90; area under the curve = 0.81).
cRecorded in adults (n = 600).
dSubset of patients with available information regarding CVC removal (n = 471 out of 474). Multivariate analysis in patients with CVC was as follows: increasing age (OR 1.03, 95%
CI 1.00–1.05, p 0.017), primary source (OR 2.25, 95% CI 1.17–4.33, p 0.015), severe sepsis or septic shock (OR 4.50, 95% CI 2.40–8.44, p <0.001), C. krusei (OR 4.16, 95% CI 1.07
–16.12, p 0.039), adequate antifungal treatment (OR 0.51, 95% CI 0.27–0.95, p 0.033), and CVC removal within 48 h (OR 0.43, 95% CI 0.21–0.87, p 0.019) (Hosmer–Lemeshow
p 0.11; area under the curve = 0.79).
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Overall 30-day mortality in our study was high (30.6%), but
similar to recent data [2,5]. Multivariate analysis suggested the
beneﬁt of prompt therapeutic measures for decreasing early
mortality, in keeping with previous reports. Furthermore, and
for the ﬁrst time, it was clearly seen that host factors and
severity of infection were the main variables inﬂuencing
mortality in the later period. These results support current
guidelines, which consider appropriate antifungal therapy and
catheter removal as the cornerstones of treatment for
candidaemia. Nonetheless, prompt CVC removal as a prog-
nostic factor of mortality remains controversial. Current data
are provided by observational studies [18,19], and some
reports have failed to demonstrate the beneﬁt of CVC
removal on outcome [16,20]. We believe CVC management
should be carefully evaluated in each patient and removal
performed whenever possible, especially if the catheter is the
suspected source of infection [19].
In light of the low percentage of adequate antifungal
treatment for C. glabrata found in this study, we considered
that azoles at any dose were inappropriate for non-susceptible
isolates [http://www.eucast.org/clinical_breakpoints/]. This
interpretation could be controversial and might have biased
the beneﬁt of antifungal therapy towards the reduction of its
effect. However, even with this deﬁnition, antifungal treatment
was associated with better early survival. Further studies are
needed to elucidate whether ﬂuconazole is a good option for
C. glabrata in terms of clinical and microbiological responses.
This study has some limitations. First, the epidemiology
described is inﬂuenced by local medical practices, which limits
the ability to generalize the results to other geographical areas.
Second, it was difﬁcult to control the analysis of prognostic
risk factors of mortality for the variable severity of illness,
since APACHE II score was only available in adult intensive
care unit patients. Nevertheless, we used other markers
related with concurrent illnesses (Charlson index) and we
explored a wide range of clinical variables to adjust for
confounding factors, which lends strength to the results. Third,
the precise number of metastatic candidiasis cases could not
TABLE 4. Univariate and multivariate logistic regression analyses of prognostic factors for late mortality (8–30 days) in 542a
patients
Variable Alive (n = 431) Died (n = 111)
Univariate analysis Multivariate analysisb
OR (95% CI) p value OR (95% CI) p value
Host factors
Age, years 64.7 (50.4–75.6) 68.7 (59.2–78.9) 1.02 (1.00–1.03) 0.001 1.03 (1.02–1.05) <0.001
Male sex 256 (59.4) 57 (51.4) 0.72 (0.48–1.10) 0.127
Charlson indexc 2 (1–3) 3 (2–4) 1.18 (1.06–1.31) 0.002
Malignancy (≤1 year) 168/430 (39.1) 44 (39.6) 1.02 (0.67–1.57) 0.913
Transplant recipient 31 (7.2) 11 (9.9) 1.42 (0.69–2.92) 0.342
HIV infection 9 (2.1) 4 (3.6) 1.75 (0.53–5.80) 0.358
Immunosuppressive therapyd 100 (23.2) 36 (32.4) 1.59 (1.00–2.51) 0.047 2.50 (1.48–4.21) 0.001
Abdominal surgery 141 (32.7) 24 (21.6) 0.57 (0.35–0.93) 0.025
Neutropenia (<500 cell/mm3) 20 (4.6) 9 (8.1) 1.81 (0.80–4.10) 0.153
Previous RRT 22 (5.1) 18 (16.2) 3.60 (1.86–6.98) <0.001 2.87 (1.34–6.15) 0.007
Intubation 65 (15.1) 46 (41.4) 3.99 (2.51–6.32) <0.001 4.24 (2.42–7.42) <0.001
Clinical data
Primary source 208 (48.3) 68 (61.3) 1.70 (1.11–2.60) 0.015 1.63 (1.03–2.61) 0.039
Catheter-related 172 (39.9) 34 (30.6) 0.67 (0.43–1.04) 0.074
Severe sepsis or septic shock 95 (22) 48 (43.2) 2.70 (1.74–4.18) <0.001 1.77 (1.05–3.00) 0.034
Antifungal agent at time of blood
culture collection
70/429 (16.3) 21 (18.9) 1.20 (0.70–2.05) 0.514
Bacteria in incident culture 75 (17.4) 25 (22.5) 1.38 (0.83–2.30) 0.216
Persistent candidaemiae 86/308 (27.9) 26/74 (35.1) 1.40 (0.82–2.40) 0.222
Candida species
C. albicans 186 (43.2) 60 (54.1) 1.55 (1.02–2.36) 0.041
C. parapsilosis 110 (25.5) 21 (18.9) 0.68 (0.40–1.15) 0.149
C. glabrata 64 (14.8) 13 (11.7) 0.76 (0.40–1.44) 0.400
C. tropicalis 35 (8.1) 7 (6.3) 0.76 (0.33–1.76) 0.525
C. krusei 7 (1.6) 3 (2.7) 1.68 (0.43–6.61) 0.456
Therapeutic measures (≤48 h)
Adequate antifungal treatment 245/429 (57.1) 60/110 (54.5) 0.90 (0.59–1.37) 0.628
CVC removalf 167/321 (52) 38/93 (40.9) 0.64 (0.40–1.02) 0.059
Values are reported as no./total no (%) or median (interquartile range).
CI, conﬁdence interval; CVC, central venous catheter; HIV, human immunodeﬁciency virus; OR, odds ratio; RRT, renal replacement therapy.
aOnly the ﬁrst episode of candidaemia was included for patients with multiple episodes. Neonates and infants younger than 1 year, cases of candidaemia caused simultaneously by
different species of Candida, deaths that occurred at days 0–7, and ﬁve adult patients who were lost to follow up in this period were excluded from the analysis.
bThe best multivariate analysis model according to Mallows′ Cp statistic included the following variables: age, immunosuppressive therapy, previous RRT, intubation, primary
source and severe sepsis or septic shock (Hosmer–Lemeshow p 0.75; area under the curve = 0.76).
cRecorded in adults (n = 513).
dIncludes corticoids, chemotherapy and other immunosuppressive drugs within the preceding month.
ePersistent candidaemia was deﬁned as persistently positive blood cultures for ≥3 days after the incident blood sample. Analysis performed in the subset of patients with follow-up
blood cultures (n = 382).
fSubset of patients with available information regarding CVC removal (n = 414 out of 417). Multivariate analysis in patients with CVC was as follows: age (OR 1.04, 95% CI 1.02–
1.05, p <0.001), previous RRT (OR 2.84, 95% CI 1.28–6.31, p 0.011), intubation (OR 3.57, 95% CI 1.98–6.45, p <0.001), primary source (OR 1.90, 95% CI 1.13–3.18, p 0.015),
severe sepsis or septic shock (OR 1.42, 95% CI 0.79–2.57, p 0.243), and CVC removal (OR 0.72, 95% CI 0.43–1.22, p 0.222) (Hosmer–Lemeshow p 0.32; area under
curve = 0.77).
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be determined because diagnostic procedures were per-
formed at the physicians’ discretion.
In conclusion, candidaemia is a severe infection that remains
associated with high morbidity and mortality. Although our
results conﬁrm that the poor prognosis may be strongly
associated with the fragile status of affected patients in whom
the risk of death is inherently high, we should focus on the
control of modiﬁable risk factors for mortality and improve
adherence to guidelines. Prompt initiation of appropriate
antifungal treatment and CVC removal could decrease early
mortality in these patients.
Acknowledgements
We thank Celine Cavallo for English language support and
Nuria Fernandez-Hidalgo and Santiago Perez-Hoyos for
statistical assistance.
Funding
This work was supported by research grants from Gilead,
MSD, Astellas and Pﬁzer and by funding from Fundacion
SEIMC-GESIDA and Ministerio de Economıa y Competitividad,
Instituto de Salud Carlos III, co-ﬁnanced by the European
Development Regional Fund “A way to achieve Europe” ERDF,
Spanish Network for the Research in Infectious Diseases
(REIPI RD12/0015). These sources of funding had no involve-
ment in the preparation of the manuscript.
Authors Contributions
BP, JGM, IRC, BA and MCE conceived, designed and coordi-
nated the study. BP, JGM, JMA, RZ, MM and BA were local
study coordinators ensuring correct data collection. OZ and
MCE were responsible for Candida species conﬁrmation and
antifungal susceptibility testing. MPA and BA were responsible
for data analysis and interpretation, and prepared the ﬁnal
version of the article. JGM, JMA, RZ, MM, PM and IRC
contributed to the original intellectual content, reviewing and
adding a critique of the report. All authors read the manuscript
and approved the ﬁnal version.
Transparency Declaration
BP has received honoraria for talks on behalf of Gilead
Sciences, Merck Sharp and Dohme, Pﬁzer, Astellas and
Novartis. JGM has received honoraria for talks on behalf of
Gilead Sciences, Merck Sharp and Dohme and Astellas. JMA
has received grant support from Astellas Pharma, Gilead
Sciences, Merck Sharp and Dohme, Pﬁzer, The Instituto de
Salud Carlos III and The Mutua Madrile~na Foundation. He has
been an advisor/consultant to Astellas Pharma, Gilead Sci-
ences, Merck Sharp and Dohme and Pﬁzer. He has received
honoraria for talks on behalf of Gilead Sciences, Merck Sharp
and Dohme, Pﬁzer and Astellas Pharma. RZ has received
honoraria for talks on behalf of Gilead Sciences, Merck Sharp
and Dohme, Pﬁzer and Astellas and a grant support from
Pﬁzer. MM has received grant support from Pﬁzer, Astellas
Pharma, Novartis, Merck Sharp and Dohme and Gilead
Sciences. PM has received honoraria for talks on behalf of
Gilead Sciences, Merck Sharp and Dohme, Pﬁzer, Astellas and
Novartis. IRC has received honoraria for talks on behalf of
Pﬁzer, Merck Sharp and Dohme, Gilead, Astellas and Novartis.
MCE has received grant support from Astellas Pharma,
bioMerieux, Gilead Sciences, Merck Sharp and Dohme, Pﬁzer,
Schering Plough, Soria Melguizo SA, Ferrer International, the
European Union, the ALBAN programme, the Spanish Agency
for International Cooperation, the Spanish Ministry of Culture
and Education, the Spanish Health Research Fund, the Instituto
de Salud Carlos III, the Ramon Areces Foundation and the
Mutua Madrile~na Foundation. He has been an advisor/consul-
tant to the Pan-American Health Organization, Astellas
Pharma, Gilead Sciences, Merck Sharp and Dohme, Pﬁzer
and Schering Plough. He has been paid for talks on behalf of
Gilead Sciences, Merck Sharp and Dohme, Pﬁzer, Astellas
Pharma and Schering Plough. BA has received grant support
from Gilead Sciences, Pﬁzer and the Instituto de Salud Carlos
III, and he has received honoraria for talks on behalf of Gilead
Sciences, Merck Sharp and Dohme, Pﬁzer, Astellas and
Novartis. MPA and OZ declare that they have no conﬂicts
of interest.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Percentages of Candida species among the 766
isolates according to each metropolitan area of Spain.
Table S1. Deﬁnitions used to classify the appropriateness
of antifungal treatment.
Table S2. Incidence of candidaemia and characteristics of
participating centres.
Table S3. Initial therapeutic measures for Candida blood-
stream episodes in paediatric and adult patients.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O245–O254
O252 Clinical Microbiology and Infection, Volume 20 Number 4, April 2014 CMI
Appendix 1
Other members of the CANDIPOP project
Jesus Guinea (Hospital General Universitario Gregorio Mara~non),
Jose Ramon Pa~no, Julio Garcıa and Carlos Garcıa (Hospital La
Paz, Madrid), Jesus Fortun, Pilar Martın and Elia Gomez (Hospital
Ramon y Cajal, Madrid), Pablo Ryan and Carolina Campelo
(Hospital Infanta Leonor, Madrid), Ignacio de los Santos and
Buenaventura Buendıa (Hospital Universitario La Princesa,
Madrid), Beatriz Perez and Mercedes Alonso (Hospital Ni~no
Jesus, Madrid), Francisca Sanz (Hospital 12 de Octubre, Madrid),
Paloma Merino and Fernando Gonzalez (Hospital Clınico,
Madrid), Miguel Gorgolas and Ignacio Gadea (Fundacion Jimenez
Dıaz, Madrid), Juan Emilio Losa and Alberto Delgado-Iribarren
(Hospital de Alcorcon, Madrid), Antonio Ramos, Yolanda
Romero and Isabel Sanchez (Hospital Majadahonda, Madrid),
Jesus Rodriguez-Ba~no and Ana Isabel Suarez (Hospital Universi-
tario Virgen Macarena, Sevilla), Ana Loza, Estrella Martın-Mazu-
elos and Ana Isabel Aller (Hospital Universitario Virgen de Valme,
Sevilla), Maite Ruiz (Hospital Universitario Virgen del Rocıo,
Sevilla), Carlos Ortiz (Hospital Sagrado Corazon, Sevilla), Monica
Chavez and Fernando L. Maroto (Hospital San Juan de Dios de
Aljarafe, Sevilla), Miguel Salavert and Javier Peman (Hospital
Universitario la Fe, Valencia), Jose Blanquer and David Navarro
(Hospital Clınico Universitario Valencia), Vicente Abril and
Concepcion Gimeno (Consorcio Hospital General Universitario
de Valencia), Juan Jose Camarena (Hospital Universitario Dr.
Peset, Valencia), Silvia Hernaez and Guillermo Ezpeleta (Hospital
de Basurto, Bilbao), Elena Bereciartua, Jose L. Hernandez
(Hospital Universitario de Cruces, Bilbao), Rosa Ana Rivas and
Rafael Ayarza (Hospital de Galdakano, Bilbao), Ana Mª Planes
(Hospital Universitari Vall d′Hebron, Barcelona), Jose Mensa and
Manel Almela (Hospital Clınic-IDIBAPS Barcelona), Merce Gurgui
and Ferran Sanchez-Reus (Hospital Universitari de Sant Pau i
Santa Creu, Barcelona), Joaquin Martinez-Montauti and Montser-
rat Sierra (Hospital de Barcelona, Barcelona), Juan Pablo
Horcajada, Luisa Sorli and Julia Gomez (Hospital del Mar,
Barcelona), Amadeu Gene and Mireia Urrea (Hospital Sant Joan
de Deu, Esplugues de Llobregat-Barcelona). Study collaborators of
CANDIPOP Project: Maricela Valerio, Mario Fernandez-Ruiz, Ana
Dıaz-Martın, Francesc Puchades, and Alessandra Mularoni.
References
1. Marchetti O, Bille J, Fluckiger U et al. Epidemiology of candidemia in
Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis
2004; 38: 311–320.
2. Poikonen E, Lyytikainen O, Anttila VJ et al. Secular trend in candidemia
and the use of ﬂuconazole in Finland, 2004–2007. BMC Infect Dis 2010;
10: 312.
3. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T,
Gaustad P. Candidemia in Norway (1991 to 2003): results from a
nationwide study. J Clin Microbiol 2006; 44: 1977–1981.
4. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of
fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011; 49: 325–334.
5. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Nationwide study
of candidemia, antifungal use, and antifungal drug resistance in Iceland,
2000 to 2011. J Clin Microbiol 2013; 51: 841–848.
6. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of
mortality in cases of Candida bloodstream infection: results from
population-based surveillance, Barcelona, Spain, from 2002 to 2003. J
Clin Microbiol 2005; 43: 1829–1835.
7. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The
epidemiology and attributable outcomes of candidemia in adults and
children hospitalized in the United States: a propensity analysis. Clin
Infect Dis 2005; 41: 1232–1239.
8. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S,
Dromer F. Recent exposure to caspofungin or ﬂuconazole inﬂuences
the epidemiology of candidemia: a prospective multicenter study
involving 2,441 patients. Antimicrob Agents Chemother 2011; 55: 532–538.
9. Kao AS, Brandt ME, Pruitt WR et al. The epidemiology of candidemia in
two United States cities: results of a population-based active surveil-
lance. Clin Infect Dis 1999; 29: 1164–1170.
10. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of
candidemia: 3-year results from the emerging infections and the
epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298–
1302.
11. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream
infections due to Candida species and in vitro susceptibilities of isolates
collected from 1998 to 2000 in a population-based active surveillance
program. J Clin Microbiol 2004; 42: 1519–1527.
12. Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and
antifungal drug resistance in candidemia: results from population-based
laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect
Dis 2012; 55: 1352–1361.
13. Rodriguez-Hernandez MJ, Ruiz-Perez de Pipaon M, Marquez-Solero M
et al. Candidemias: multicentre analysis in 16 hospitals in Andalusia
(Spain). Enferm Infecc Microbiol Clin 2011; 29: 328–333.
14. Peman J, Canton E, Quindos G et al. Epidemiology, species distribution
and in vitro antifungal susceptibility of fungaemia in a Spanish multicen-
tre prospective survey. J Antimicrob Chemother 2012; 67: 1181–1187.
15. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock
attributed to Candida infection: importance of empiric therapy and
source control. Clin Infect Dis 2012; 54: 1739–1746.
16. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous
catheter in patients with candidemia does not improve outcome:
analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis
2010; 51: 295–303.
17. Grim SA, Berger K, Teng C et al. Timing of susceptibility-based
antifungal drug administration in patients with Candida bloodstream
infection: correlation with outcomes. J Antimicrob Chemother 2012; 67:
707–714.
18. Andes DR, Safdar N, Baddley JW et al. Impact of treatment strategy on
outcomes in patients with candidemia and other forms of invasive
candidiasis: a patient-level quantitative review of randomized trials. Clin
Infect Dis 2012; 54: 1110–1122.
19. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de
Pipaon M, Hernandez-Caballero C, Lepe-Jimenez JA. Impact on
hospital mortality of catheter removal and adequate antifungal therapy
in Candida spp. bloodstream infections. J Antimicrob Chemother 2013; 68:
206–213.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O245–O254
CMI Puig-Asensio et al. Predictors of mortality in candidaemia O253
20. Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous
catheter removal on outcome in patients with candidaemia. Clin
Microbiol Infect 2007; 13: 788–793.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 1987; 40: 373–383.
22. Bone RC, Balk RA, Cerra FB et al. Deﬁnitions for sepsis and organ
failure and guidelines for the use of innovative therapies in sepsis.
ACCP/SCCM Consensus Conference Committee. American College
of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:
1644–1655.
23. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the
diagnosis and management of intravascular catheter-related infection:
2009 update by the Infectious Diseases Society of America. Clin Infect
Dis 2009; 49: 1–45.
24. Luo G, Mitchell TG. Rapid identiﬁcation of pathogenic fungi directly
from cultures by using multiplex PCR. J Clin Microbiol 2002; 40: 2860–
2865.
25. White TJ, Bruns TD, Lee SB, Taylor JW. Ampliﬁcation and direct
sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis
MA, Gelfand DH, Sninsky JJ, Whit TJ, eds, PCR protocols: a guide to
methods and applications. San Diego, CA: Academic Press, Inc., 1990;
315–322.
26. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F et al. EUCAST
deﬁnitive document EDef 7.1: method for the determination of broth
dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol
Infect 2008; 14: 398–405.
27. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. EUCAST
technical note on the EUCAST deﬁnitive document EDef 7.2: method
for the determination of broth dilution minimum inhibitory concen-
trations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin
Microbiol Infect 2012; 18: E246–E247.
28. Rodriguez D, Almirante B, Park BJ et al. Candidemia in neonatal
intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006; 25: 224–
229.
29. Peman J, Canton E, Linares-Sicilia MJ et al. Epidemiology and antifungal
susceptibility of bloodstream fungal isolates in pediatric patients: a
Spanish multicenter prospective survey. J Clin Microbiol 2011; 49: 4158–
4163.
30. Almirante B, Rodriguez D, Cuenca-Estrella M et al. Epidemiology, risk
factors, and prognosis of Candida parapsilosis bloodstream infections:
case–control population-based surveillance study of patients in Barce-
lona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681–1685.
31. Hope WW, Castagnola E, Groll AH et al. ESCMID* guideline for the
diagnosis and management of Candida diseases 2012: Prevention and
management of invasive infections in neonates and children caused by
Candida spp. Clin Microbiol Infect 2012; 18(Suppl 7): 38–52.
32. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for
the management of candidiasis: 2009 update by the Infectious Diseases
Society of America. Clin Infect Dis 2009; 48: 503–535.
33. Peman J, Canton E, Orero A, Viudes A, Frasquet J, Gobernado M.
Epidemiology of candidemia in Spain—multicenter study. Rev Iberoam
Micol 2002; 19: 30–35.
34. Lin MY, Carmeli Y, Zumsteg J et al. Prior antimicrobial therapy and risk
for hospital-acquired Candida glabrata and Candida krusei fungemia: a
case–case–control study. Antimicrob Agents Chemother 2005; 49: 4555–
4560.
35. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA.
Candida glabrata fungemia: experience in a tertiary care center. Clin
Infect Dis 2005; 41: 975–981.
36. Cuenca-Estrella M, Rodriguez D, Almirante B et al. In vitro susceptibil-
ities of bloodstream isolates of Candida species to six antifungal agents:
results from a population-based active surveillance programme, Barce-
lona, Spain, 2002–2003. J Antimicrob Chemother 2005; 55: 194–199.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O245–O254
O254 Clinical Microbiology and Infection, Volume 20 Number 4, April 2014 CMI
